Production of therapeutic antibodies with controlled fucosylation

N Yamane-Ohnuki, M Satoh - MAbs, 2009 - Taylor & Francis
N Yamane-Ohnuki, M Satoh
MAbs, 2009Taylor & Francis
ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent cytotoxicity;
Fc, antibody constant region; FcγRIIIa, human Fcγ-receptor IIIa; IgG, immunoglobulin G; NK
cell, natural killer cell; CHO, Chinese hamster ovary; EPO, erythropoietin; Glc, glucose; Man,
mannose; GlcNAc, N-acetylglucosamine; Gal, galactose; NANA; N-acetylneuraminic acid;
FUT8, α-1, 6 fucosyltransferase; GMD, GDP-mannose 4, 6-dehydratase; FX, GDP-keto-6-
deoxymannose 3, 5-epimerase/4-reductase; GFT, GDP-fucose transporter; siRNA, short …
ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent cytotoxicity; Fc, antibody constant region; FcγRIIIa, human Fcγ-receptor IIIa; IgG, immunoglobulin G; NK cell, natural killer cell; CHO, Chinese hamster ovary; EPO, erythropoietin; Glc, glucose; Man, mannose; GlcNAc, N-acetylglucosamine; Gal, galactose; NANA; N-acetylneuraminic acid; FUT8, α-1,6 fucosyltransferase; GMD, GDP-mannose 4,6-dehydratase; FX, GDP-keto-6-deoxymannose 3,5-epimerase/4-reductase; GFT, GDP-fucose transporter; siRNA, short interfering RNA; GnTIII, β-1,4-N-acetylglucosaminyltransferase; ManII, α-mannosidase II
Taylor & Francis Online